LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Immunocore Holdings PLC ADR

Uždarymo kaina

28.35 -4.03

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.21

Max

28.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-33M

-24M

Pardavimai

3.8M

84M

Pelnas, tenkantis vienai akcijai

-0.49

Pelno marža

-28.281

Darbuotojai

493

EBITDA

-8M

-16M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+130.63% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.6M

1.5B

Ankstesnė atidarymo kaina

32.38

Ankstesnė uždarymo kaina

28.35

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-11 23:48; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

2025-05-11 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

2025-05-11 23:45; UTC

Rinkos pokalbiai

Oil Rises Amid Improved Market Mood -- Market Talk

2025-05-11 23:38; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Aristocrat Has Significant Firepower for M&A -- Market Talk

2025-05-11 23:36; UTC

Rinkos pokalbiai

Global Markets Uncertain About US-China Trade News -- Market Talk

2025-05-11 23:35; UTC

Rinkos pokalbiai

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

2025-05-11 23:33; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

2025-05-11 23:32; UTC

Svarbiausios naujienos

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

2025-05-11 22:44; UTC

Rinkos pokalbiai

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

2025-05-11 22:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

2025-05-11 20:19; UTC

Svarbiausios naujienos

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

2025-05-11 16:00; UTC

Svarbiausios naujienos

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

2025-05-11 11:00; UTC

Svarbiausios naujienos

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

2025-05-11 08:00; UTC

Svarbiausios naujienos

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

2025-05-11 01:00; UTC

Svarbiausios naujienos

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

2025-05-11 01:00; UTC

Svarbiausios naujienos

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

2025-05-10 21:54; UTC

Svarbiausios naujienos

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

2025-05-10 17:12; UTC

Svarbiausios naujienos

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

2025-05-10 15:41; UTC

Svarbiausios naujienos

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

2025-05-10 12:00; UTC

Svarbiausios naujienos

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

2025-05-10 09:30; UTC

Svarbiausios naujienos

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

2025-05-10 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-05-10 03:52; UTC

Svarbiausios naujienos

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

2025-05-09 23:51; UTC

Įsigijimai, susijungimai, perėmimai

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

2025-05-09 22:06; UTC

Rinkos pokalbiai

Arm Holdings Remains a Strong Growth Story -- Market Talk

2025-05-09 21:37; UTC

Svarbiausios naujienos

U.S. Sets August Deadline for Debt Ceiling -- WSJ

2025-05-09 21:10; UTC

Svarbiausios naujienos

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

2025-05-09 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-05-09 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-05-09 20:42; UTC

Svarbiausios naujienos

Stocks Get a Break From Trade Chaos -- WSJ

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

130.63% į viršų

12 mėnesių prognozė

Vidutinis 65.5 USD  130.63%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

9

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

27.895 / 30.16Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.